Oramed Pharm (ORMP) Stock Statistics & Valuation Metrics
Total Valuation
Oramed Pharm has a market cap or net worth of ILA 537.61M. The enterprise value is ILA 154.55M.
- Market Cap
- ILA 537.61M
- Enterprise Value
- ILA 154.55M
Share Statistics
Oramed Pharm has 41,597,355 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 41,597,355
- Owned by Insiders
- 25.16%
- Owned by Institutions
- 0.71%
Financial Efficiency
Oramed Pharm’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is -6.05%.
- Return on Equity (ROE)
- 0.32
- Return on Assets (ROA)
- 0.28
- Return on Invested Capital (ROIC)
- -6.05%
- Return on Capital Employed (ROCE)
- -0.07
- Revenue Per Employee
- 153.85K
- Profits Per Employee
- 4.93M
- Employee Count
- 13
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Oramed Pharm is 0.97. Oramed Pharm’s PEG ratio is 0.00.
- PE Ratio
- 0.97
- PS Ratio
- 0.00
- PB Ratio
- 0.53
- Price to FCF
- -31.82
- Price to Operating Cash Flow
- -30.29
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Oramed Pharm had revenue of 2.00M and earned 64.05M in profits. Earnings per share was 1.53.
- Revenue
- 2.00M
- Gross Profit
- 13.00K
- Operating Income
- -15.09M
- Pretax Income
- 75.32M
- Net Income
- 64.05M
- EBITDA
- 75.44M
- Earnings Per Share (EPS)
- 1.53
Cash Flow
In the last 12 months, operating cash flow was -5.57M and capital expenditures 194,711, giving a free cash flow of -5.37M billion.
- Operating Cash Flow
- -5.57M
- Free Cash Flow
- -5.37M
- Free Cash Flow per Share
- -0.13
Dividends & Yields
Oramed Pharm pays an annual dividend of ILA 78.58, resulting in a dividend yield of ―
- Dividend Per Share
- ILA 78.58
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.14%
- Earnings Yield
- 103.67%
Stock Price Statistics
- Beta
- 0.52
- 52-Week Price Change
- 83.39%
- 50-Day Moving Average
- 1399.68
- 200-Day Moving Average
- 1208.46
- Relative Strength Index (RSI)
- 46.39
- Average Volume (3m)
- 4,619
Important Dates
Oramed Pharm upcoming earnings date is Jul 14, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Jul 15, 2026
- Next Earnings Date
- Jul 14, 2027
- Ex-Dividend Date
- Jan 16, 2026
Financial Position
Oramed Pharm as a current ratio of 6.98, with Debt / Equity ratio of 0.41%
- Current Ratio
- 6.98
- Quick Ratio
- 6.98
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.60
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Oramed Pharm has paid 11.31M in taxes.
- Income Tax
- 11.31M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Oramed Pharm EV to EBITDA ratio is 1.03, with an EV/FCF ratio of -29.12.
- EV to Sales
- 0.00
- EV to EBITDA
- 1.03
- EV to Free Cash Flow
- -29.12
- EV to Operating Cash Flow
- -28.10
Balance Sheet
Oramed Pharm has ILA 50.61M in cash and marketable securities with ILA 733.00K in debt, giving a net cash position of ILA 49.88M billion.
- Cash & Marketable Securities
- ILA 50.61M
- Total Debt
- ILA 733.00K
- Net Cash
- ILA 49.88M
- Net Cash Per Share
- ILA 1.20
- Tangible Book Value Per Share
- ILA 7.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Oramed Pharm is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―